William Blair Equities Analysts Lift Earnings Estimates for Repligen Co. (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGEN) – Analysts at William Blair lifted their Q1 2024 EPS estimates for Repligen in a note issued to investors on Monday, November 13th. William Blair analyst M. Larew now anticipates that the biotechnology company will earn $0.35 per share for the quarter, up from their prior estimate of $0.34. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen’s Q2 2024 earnings at $0.39 EPS, Q3 2024 earnings at $0.47 EPS, Q4 2024 earnings at $0.57 EPS and FY2024 earnings at $1.77 EPS.

RGEN has been the topic of a number of other research reports. UBS Group decreased their target price on shares of Repligen from $210.00 to $170.00 and set a “buy” rating on the stock in a research report on Thursday, November 2nd. KeyCorp decreased their target price on shares of Repligen from $240.00 to $210.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 1st. Wells Fargo & Company began coverage on shares of Repligen in a research report on Thursday, July 20th. They set an “overweight” rating and a $185.00 price target on the stock. JPMorgan Chase & Co. reduced their price target on shares of Repligen from $200.00 to $180.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 17th. Finally, Craig Hallum reduced their price target on shares of Repligen from $207.00 to $200.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $189.55.

Repligen Price Performance

NASDAQ RGEN opened at $155.93 on Wednesday. The firm’s 50-day moving average is $151.04 and its two-hundred day moving average is $157.63. Repligen has a 12 month low of $110.45 and a 12 month high of $210.21. The stock has a market capitalization of $8.71 billion, a P/E ratio of 76.81, a PEG ratio of 3.53 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.09. Repligen had a net margin of 17.29% and a return on equity of 6.08%. The firm had revenue of $141.20 million during the quarter, compared to analyst estimates of $140.68 million. During the same quarter in the prior year, the firm posted $0.77 earnings per share. Repligen’s quarterly revenue was down 29.6% on a year-over-year basis.

Insider Buying and Selling

In related news, insider Christine Gebski sold 3,788 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $147.13, for a total transaction of $557,328.44. Following the sale, the insider now directly owns 28,787 shares in the company, valued at $4,235,431.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Christine Gebski sold 3,788 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $147.13, for a total transaction of $557,328.44. Following the sale, the insider now directly owns 28,787 shares in the company, valued at $4,235,431.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Karen A. Dawes sold 850 shares of the stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $171.38, for a total transaction of $145,673.00. Following the completion of the transaction, the director now owns 83,741 shares in the company, valued at $14,351,532.58. The disclosure for this sale can be found here. Insiders own 1.10% of the company’s stock.

Hedge Funds Weigh In On Repligen

Several hedge funds have recently added to or reduced their stakes in RGEN. PNC Financial Services Group Inc. increased its stake in Repligen by 6.2% in the first quarter. PNC Financial Services Group Inc. now owns 5,723 shares of the biotechnology company’s stock valued at $1,077,000 after purchasing an additional 333 shares during the last quarter. Great West Life Assurance Co. Can increased its holdings in shares of Repligen by 8.2% in the 1st quarter. Great West Life Assurance Co. Can now owns 28,126 shares of the biotechnology company’s stock valued at $5,427,000 after acquiring an additional 2,143 shares during the period. Raymond James Trust N.A. increased its holdings in shares of Repligen by 37.4% in the 1st quarter. Raymond James Trust N.A. now owns 2,331 shares of the biotechnology company’s stock valued at $438,000 after acquiring an additional 634 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Repligen by 5.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 229,785 shares of the biotechnology company’s stock valued at $43,221,000 after acquiring an additional 11,121 shares during the period. Finally, Sei Investments Co. increased its holdings in shares of Repligen by 18.5% in the 1st quarter. Sei Investments Co. now owns 59,917 shares of the biotechnology company’s stock valued at $11,331,000 after acquiring an additional 9,352 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.